Oxford based liver AI diagnosis company seeks to list on Nasdaq
Perspectum, the Oxford-headquartered digital tech that helps clinicians provide better care for patients with liver disease, has applied to liston the Nasdaq Global Select Market under the ticker symbol “SCAN.”
The offering is subject to market conditions.
The firm hopes to raise the funds giving it a market valuation of up to $637 million, according to reports.
Perspectum's software products combine image formation, magnetic resonance (MR) image analysis, and artificial intelligence (AI) to support diagnosis, treatment decision-making, and monitoring of the progression of chronic metabolic diseases, multi-organ pathologies, and cancer, and determine whether the patient is responding to therapy.
Its product portfolio comprises cloud-based AI-driven software that uses medical images. Its flagship AI-driven product, LiverMultiScan, has been cleared by the FDA for non-invasive diagnosis and monitoring of liver disorders. The company's SaaS platform products are currently enabled at approximately 350 locations worldwide.
Perspectum Group was founded in 2012 and reported $9 million in revenue for the 12 months ended March 31, 2021.
